Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Small molecule immunomodulatory drugs: challenges and approaches for balancing efficacy with toxicity.

Haley PJ.

Toxicol Pathol. 2012;40(2):261-6. doi: 10.1177/0192623311427569. Epub 2011 Nov 14. Review.

PMID:
22083586
2.

Species selection considerations for preclinical toxicology studies for biotherapeutics.

Bussiere JL.

Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):871-7. doi: 10.1517/17425255.4.7.871 . Review.

PMID:
18624676
3.

Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.

EFSA GMO Panel Working Group on Animal Feeding Trials.

Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Review.

PMID:
18328408
4.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
5.

Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.

Muller PY, Brennan FR.

Clin Pharmacol Ther. 2009 Mar;85(3):247-58. doi: 10.1038/clpt.2008.273. Epub 2009 Jan 28. Review.

PMID:
19177065
6.

Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies.

Aardema MJ, MacGregor JT.

Mutat Res. 2002 Jan 29;499(1):13-25. Review.

PMID:
11804602
7.

Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.

Piccotti JR, Lebrec HN, Evans E, Herzyk DJ, Hastings KL, Burns-Naas LA, Gourley IS, Wierda D, Kawabata TT.

J Immunotoxicol. 2009 Mar;6(1):1-10. doi: 10.1080/15476910802656440.

PMID:
19519157
8.

Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.

Singh SS.

Curr Drug Metab. 2006 Feb;7(2):165-82. Review.

PMID:
16472106
9.

Anticancer Drug Development: The Way Forward.

Connors T.

Oncologist. 1996;1(3):180-181.

10.

Alternative strategies for toxicity testing of species-specific biopharmaceuticals.

Bussiere JL, Martin P, Horner M, Couch J, Flaherty M, Andrews L, Beyer J, Horvath C.

Int J Toxicol. 2009 May-Jun;28(3):230-53. doi: 10.1177/1091581809337262. Review.

PMID:
19546261
11.

Genotoxicity of 1,3-butadiene and its epoxy intermediates.

Walker VE, Walker DM, Meng Q, McDonald JD, Scott BR, Seilkop SK, Claffey DJ, Upton PB, Powley MW, Swenberg JA, Henderson RF; Health Review Committee.

Res Rep Health Eff Inst. 2009 Aug;(144):3-79.

PMID:
20017413
12.

Immunotoxicant screening and prioritization in the twenty-first century.

Luebke R.

Toxicol Pathol. 2012;40(2):294-9. doi: 10.1177/0192623311427572. Epub 2011 Nov 21. Review.

PMID:
22105646
13.

Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.

Lebrec H, Narayanan P, Nims R.

J Appl Toxicol. 2010 Jul;30(5):387-96. doi: 10.1002/jat.1551. Review. Erratum in: J Appl Toxicol. 2011 Mar;31(2):190.

PMID:
20589744
14.

Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.

Brennan FR, Cauvin A, Tibbitts J, Wolfreys A.

Drug Dev Res. 2014 May;75(3):115-61. doi: 10.1002/ddr.21173. Epub 2014 Apr 29. Review.

PMID:
24782266
15.

Relation of preclinical toxicology to findings in early clinical trials.

Grieshaber CK, Marsoni S.

Cancer Treat Rep. 1986 Jan;70(1):65-72.

PMID:
3943115
16.

The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease.

't Hart BA, Abbott DH, Nakamura K, Fuchs E.

Drug Discov Today. 2012 Nov;17(21-22):1160-5. doi: 10.1016/j.drudis.2012.06.009. Epub 2012 Jun 21.

PMID:
22728226
17.
18.

In-vitro techniques: can they replace animal testing?

Pearson RM.

Hum Reprod. 1986 Dec;1(8):559-60.

PMID:
3818914
19.

Informed toxicity assessment in drug discovery: systems-based toxicology.

Mayne JT, Ku WW, Kennedy SP.

Curr Opin Drug Discov Devel. 2006 Jan;9(1):75-83. Review.

PMID:
16445119
20.

Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.

Martin PL, Weinbauer GF.

Int J Toxicol. 2010 Dec;29(6):552-68. doi: 10.1177/1091581810378896. Epub 2010 Oct 6. Review.

PMID:
20926830

Supplemental Content

Support Center